INTRODUCTION {#s1}
============

Autoimmune liver diseases (AILD) cover a spectrum of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH) and immunoglobulin G4 (IgG4) related cholangitis. These are all relatively rare diseases but result in significant morbidity and mortality. A considerable proportion of patients with AILD eventually progress to end-stage liver disease. In Europe, AILD represent a major indication for liver transplantation. As complex disorders, AILD develop from the interactions between a variety of genetic and environmental factors \[[@R1]--[@R3]\]. Until now, the pathogenesis of PBC, PSC, AIH or IgG4 related cholangitis has not been fully elaborated.

Previous epidemiological studies have reported that the incidence of AILD varies over time and space \[[@R4]\]. It is widely accepted that, in genetically susceptible individuals, environmental risk factors might contribute to the onset of disease \[[@R2]\]. The rapid economical development of society leads to changes in lifestyle, hygienic and psychosocial conditions. The influence of the socioeconomic status on the incidence of AILD has never been studied. Herein, we systematically reviewed epidemiological studies of AILD from all over the world, and explored the relationship between the AILD incidence and the socioeconomic status. In this study, the human development index (HDI) was applied as an indicator to reflect socioeconomic status. We are convinced that this study might provide additional insight into the pathogenesis and etiology of these diseases.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Among the 43 enrolled studies, 22 reported the incidence of PBC \[[@R5]--[@R26]\], while 13 were relevant for PSC \[[@R13]-[@R14], [@R17], [@R27]-[@R36]\], and 14 provided information about epidemiology of AIH \[[@R4], [@R13]-[@R14], [@R17], [@R37]-[@R46]\]. No studies mentioned the population incidence of IgG4 related cholangitis, presumably because it is relatively rare as a new disease entity.

Primary characteristics of the enrolled studies including first author, publication year, research period, country, continent, criteria of disease identification, incidence (per 100,000 per year) and HDI were summarized in Table [1](#T1){ref-type="table"}. A majority of the studies (29 of 42) were conducted in Europe, while six studies were conducted in North America, six and two were conducted in Asia and Australia, respectively.

###### Primary characteristics of the included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study               Publication year   Disease   Disease identification                                                                Country          Continent       Research period   Incidence per 100,000 per year   HDI
  ------------------- ------------------ --------- ------------------------------------------------------------------------------------- ---------------- --------------- ----------------- -------------------------------- -------------------
  Triger^8^           1980               PBC       Cholestasis; AMA                                                                      United Kingdom   Europe          1977-1979         0.58                             0.735

  Eriksson^9^         1984               PBC       Cholestasis; AMA                                                                      Sweden           Europe          1973-1982         1.37                             0.776

  Borda^10^           1989               PBC       Cholestasis; AMA                                                                      Spain            Europe          1974-1987         1974: 0.41\                      1974: NA\
                                                                                                                                                                                            1987: 2.52                       1987: 0.755

  Myszor^11^          1990               PBC       Cholestasis; AMA; liver biopsy                                                        United Kingdom   Europe          1965-1987         1987: 1.98                       1987: 0.768

  Danielsson^12^      1990               PBC       (Cholestasis + AMA) or liver biopsy                                                   Sweden           Europe          1973-1982         1.33                             0.776

  Almdal^13^          1991               PBC       Registry-based                                                                        Denmark          Europe          1981-1985         0.90                             0.788

  Remmel^14^          1995               PBC       (Cholestasis + AMA) or liver biopsy                                                   Estonia          Europe          1973-1992         0.23                             0.684

  Metcalf^15^         1997               PBC       2 of 3: AMA positive; abnormal liver function; liver biopsy                           United Kingdom   Europe          1987-1994         2.20                             0.839

  Berdal^16^          1998               PBC       Cholestasis; AMA; liver biopsy                                                        Norway           Europe          1985-1994         1.20                             0.843

  Berdal^16^          1998               PSC       Cholangiography; exclusion of alternatives                                            Norway           Europe          1985-1994         0.70                             0.843

  Berdal^16^          1998               AIH       Original IAHG criteria^6^                                                             Norway           Europe          1985-1994         1.60                             0.843

  Boberg^17^          1998               PBC       Cholestasis; AMA; liver biopsy                                                        Norway           Europe          1986-1995         1.62                             0.849

  Boberg^17^          1998               PSC       Cholestasis; Cholangiography; liver biopsy                                            Norway           Europe          1986-1995         1.31                             0.849

  Boberg^17^          1998               AIH       Original IAHG criteria^6^                                                             Norway           Europe          1986-1995         1.90                             0.849

  James^18^           1999               PBC       2 of 3: AMA positive; abnormal liver function; liver biopsy                           United Kingdom   Europe          1987-1994         1987: 2.30\                      1987: 0.758\
                                                                                                                                                                                            1994: 3.22                       1994: 0.806

  Kim^19^             2000               PBC       (Cholestasis + AMA) or liver biopsy                                                   USA              North America   1975-1995         2.70                             0.847

  Whalley^20^         2007               PBC       Cholestasis; AMA                                                                      United Kingdom   Europe          2003-2004         3.50                             0.881

  Whalley^20^         2007               PSC       Cholangiography                                                                       United Kingdom   Europe          2003-2004         2.00                             0.881

  Whalley^20^         2007               AIH       Abnormal liver function; presence of autoantibodies                                   United Kingdom   Europe          2003-2004         3.00                             0.881

  Rautiainen^21^      2007               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Finland          Europe          1988-1999         1988: 1.20\                      1988: 0.784\
                                                                                                                                                                                            1999: 1.70                       1999: 0.836

  Pla^22^             2007               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Spain            Europe          1990-2002         1.72                             0.794

  Myers^23^           2009               PBC       Cholestasis; AMA                                                                      Canada           North America   1996-2002         3.03                             0.868

  Chong^24^           2010               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Brunei           Asia            2007              1.03                             0.841

  Delgado^25^         2012               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Israel           Asia            1990-2010         1990-1999: 1.00\                 1990-1999: 0.814\
                                                                                                                                                                                            2000-2010: 2.00                  2000-2010: 0.865

  Baldursdottir^26^   2012               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Iceland          Europe          1991-2010         1991-2000: 2.00\                 1991-2000: 0.829\
                                                                                                                                                                                            2001-2010: 2.50                  2001-2010: 0.872

  Ngu^27^             2012               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       New Zealand      Australia       2008              0.80                             0.899

  Koulentaki^28^      2014               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Greece           Europe          1990-2010         2.09                             0.803

  Boonstra^29^        2014               PBC       2 of 3: Cholestasis; AMA positive; liver biopsy                                       Netherlands      Europe          2000-2007         1.10                             0.885

  Escorsell^30^       1994               PSC       Cholangiography                                                                       Spain            Europe          1984-1988         0.04                             0.733

  Hurlburt^31^        2002               PSC       Cholangiography                                                                       USA              North America   1984-2000         0                                0.861

  Ang^32^             2002               PSC       Cholangiography; exclusion of alternatives                                            Singapore        Asia            1989-1998         1.33                             0.767

  Bambha^33^          2003               PSC       Cholestasis; Cholangiography or liver biopsy; exclusion of alternatives               USA              North America   1976-2000         0.90                             0.854

  Kingham^34^         2004               PSC       Abnormal liver function; Cholangiography; liver biopsy                                United Kingdom   Europe          1984-2003         0.91                             0.813

  Kaplan^35^          2007               PSC       Abnormal liver function; Cholangiography or liver biopsy; exclusion of alternatives   Canada           North America   2000-2005         0.92                             0.880

  Card^36^            2008               PSC       Registry-based                                                                        United Kingdom   Europe          1990-2001         0.41                             0.876

  Lindkvist^37^       2010               PSC       Cholestasis; Cholangiography or liver biopsy; exclusion of alternatives               Sweden           Europe          1992-2005         1.22                             0.855

  Toy^38^             2011               PSC       Cholangiography or liver biopsy                                                       USA              North America   2000-2006         0.41                             0.897

  Boonstra^39^        2013               PSC       Cholestasis; Cholangiography or liver biopsy; exclusion of alternatives               Netherlands      Europe          2000-2007         0.50                             0.885

  Ritland^40^         1985               AIH       Abnormal liver function; presence of autoantibodies; exclusion of alternatives        Norway           Europe          1981              1.19                             0.798

  Tanner^41^          1989               AIH       Abnormal liver function; liver biopsy; exclusion of alternatives                      United Kingdom   Europe          1971-1987         0.42                             0.735

  Lee^42^             2001               AIH       Original IAHG criteria^6^                                                             Singapore        Asia            1990-1996         0.60                             0.761

  Primo^43^           2004               AIH       Original^6^, revised^7^, or simplified criteria^5^                                    Spain            Europe          1990-2003         0.83                             0.796

  Werner^44^          2008               AIH       Revised IAHG criteria^7^                                                              Sweden           Europe          1990-2003         0.85                             0.848

  Primo^45^           2009               AIH       Revised IAHG criteria^7^                                                              Spain            Europe          2003              1.07                             0.837

  Ngu^46^             2010               AIH       Revised^7^ or simplified criteria^5^                                                  New Zealand      Austrilia       2008              1.70                             0.899

  Delgado^4^          2013               AIH       Simplified criteria^5^                                                                Israel           Asia            1995-2010         0.67                             0.849

  Grønbæk^47^         2014               AIH       Registry-based                                                                        Denmark          Europe          1994-2012         1.68                             0.864

  Van Gerven^48^      2014               AIH       Revised^7^ or simplified criteria^5^                                                  Netherlands      Europe          2000-2010         1.10                             0.889

  Yoshizawa^49^       2015               AIH       Revised IAHG criteria                                                                 Japan            Asia            2004-2014         1.52                             0.882
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HDI: human development index; PBC: primary biliary cirrhosis; PSC: primary sclerosing cholangitis; AIH: autoimmune hepatitis; AMA: anti-mitochondrial antibodies; IAHG: international autoimmune hepatitis group; NA: not available.

The national incidence of AILD varied among the studies performed in different countries or during different study periods. A relatively higher incidence of disease was associated with a higher national HDI. However, the included studies were generally conducted in countries with higher socioeconomic development. A total of 28 studies were performed in countries with very high HDI, 14 in high HDI countries, and one in medium HDI country. Few studies investigated the incidence of AILD in less developed countries with medium or low HDI.

PBC incidence and HDI {#s2_2}
---------------------

The incidence of PBC was positively correlated with the national HDI according to Pearson correlation and linear regression analysis, but there was no statistical significance \[β = 5.582 ± 6.343 (95% CI), r = 0.348, *P* = 0.082\] (Figure [1a](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). We noticed that the incidence of PBC in New Zealand, Australia was particularly low compared to those reported in other locations for a similar period.\[[@R24]\] After removing the study by Ngu et al.,\[[@R24]\] a significantly positive correlation between HDI and PBC incidence was observed \[β = 7.645 ± 6.320 (95% CI), r = 0.463, *P* = 0.020\] (Figure [1b](#F1){ref-type="fig"}).

###### Correlation between AILD incidence and HDI, along with its three dimensions

  Disease       Parameters          HDI                  Health Index         Education index     Income Index
  ------------- ------------------- -------------------- -------------------- ------------------- --------------
  PBC           R                   0.348                0.422                −0.650              −0.284
  β             5.582               2.193                −2.370               −0.131              
  95% CI of β   \[−0.761, 1.925\]   \[0.159, 4.227\]     \[−3.565, −1.175\]   \[−0.316, 0.055\]   
  P             0.082               0.036                \< 0.01              0.159               
  PSC           R                   0.116                0.180                0.235               0.599
  β             1.355               2.605                0.761                5.285               
  95% CI of β   \[−6.346, 9.055\]   \[−6.838, 12.049\]   \[−1.325, 2.847\]    \[0.594, 9.976\]    
  P             0.706               0.556                0.439                0.031               
  AIH           R                   0.638                0.187                0.219               0.649
  β             8.784               2.165                0.916                7.575               
  95% CI of β   \[2.116, 15.452\]   \[−4.972, 9.302\]    \[−1.656, 3.488\]    \[1.987, 13.164\]   
  P             0.014               0.521                0.453                0.012               

AILD: autoimmune liver disease; HDI: human development index; PBC: primary biliary cirrhosis; PSC: primary sclerosing cholangitis; AIH: autoimmune hepatitis; CI: confidence interval.

![National incidence of autoimmune liver diseases and human development index\
**a.** Overall incidence of PBC (r = 0.348, *P* = 0.082); **b.** Incidence of PBC after exclusion of the study conducted in New Zealand (r = 0.463, *P* = 0.020); **c.** Incidence of PBC in Europe (r = 0.455, *P* = 0.044); **d.** Incidence of PSC (r = 0.116, *P* = 0.706); **e.** Overall incidence of AIH (r = 0.638, *P*= 0.019); **f.** Incidence of AIH in Europe (r = 0.644, *P* = 0.045). Best-fit lines (solid) and the 95% confidence band of the best-fit line (dashed) by linear regression are indicated.](oncotarget-07-46273-g001){#F1}

In subgroup analysis for geographic location (continent), Figure [1c](#F1){ref-type="fig"} demonstrated that the PBC incidence in Europe was statistically, positively correlated with the national HDI \[β = 7.245 ± 7.021 (95% CI), r = 0.455, *P* = 0.044\]. The relationship between the HDI and PBC incidence in Asia, North America or Australia was impossible to be identified due to the limited number of studies involved.

PSC incidence and HDI {#s2_3}
---------------------

There was no correlation between the PSC incidence and the national HDI (r = 0.116, *P* = 0.706) (Figure [1d](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Subsequent subgroup analysis for geographic location (continent) indicated no correlation between the incidence of PSC and HDI in Europe (r = 0.508, *P* = 0.198) or in North America (r = −0.030, *P* = 0.970).

AIH incidence and HDI {#s2_4}
---------------------

We found a significantly positive correlation between the national HDI and AIH incidence \[β = 8.784 ± 6.668 (95% CI), r = 0.638, *P* = 0.014\] (Figure [1e](#F1){ref-type="fig"}, Table [2](#T2){ref-type="table"}). In Europe, the national incidence of AIH was positively correlated with the HDI \[β = 10.132 ± 9.817 (95% CI), r = 0.644, *P* = 0.045\] (Figure [1f](#F1){ref-type="fig"}). Limited data prevented further analysis about this relationship in other continents.

Disease incidence in countries with different HDIs {#s2_5}
--------------------------------------------------

Studies investigating the PBC incidence were classified into three groups based on the fact if they were conducted in very high, high or medium HDI countries. ANOVA analysis revealed no significant difference among the groups (*P* = 0.074) (Figure [2a](#F2){ref-type="fig"}). Countries with a very high HDIs presented a mean PBC incidence of 1.981 per 100,000 per year (Standard deviation (SD): 0.842), while high HDI countries had a mean PBC incidence of 1.544 per 100,000 per year (SD: 0.641). Similarly, we removed the study conducted in New Zealand, Australia by Ngu et al.,\[[@R24]\] and found that PBC was significantly more prevalent in countries with higher HDIs (*P* = 0.045 by ANOVA).

![National incidence of autoimmune liver diseases in countries with different development levels\
**a.** Incidence of PBC; **b.** Incidence of PSC; **c.** Incidence of AIH. One-way analysis of variance or unpaired t test was conducted in the comparison.](oncotarget-07-46273-g002){#F2}

Compared to countries with very high HDIs (mean incidence: 0.844 per 100,000 per year, SD: 0.542), high HDI countries had no difference of PSC incidence (mean incidence: 0.685 per 100,000 per year, SD: 0.912) (*P* = 0.847 by unpaired t test) (Figure [2b](#F2){ref-type="fig"}).

Very high HDI countries had a mean AIH incidence of 1.509 per 100,000 per year (SD: 0.662), significantly higher than in countries with high HDIs (mean incidence: 0.760 per 100,000 per year, SD: 0.332) (*P* = 0.017 by unpaired t test) (Figure [2c](#F2){ref-type="fig"}).

Disease incidence with three dimensions of HDI {#s2_6}
----------------------------------------------

We further evaluated the correlations between the incidence of AILD and the three dimensions of HDI (Table [2](#T2){ref-type="table"}). Interestingly, the incidence of PBC was positively correlated with life expectancy at birth (health index) \[β = 2.193 ± 2.034 (95% CI), r = 0.422, *P* = 0.036\], but showed a negative correlation with the education index \[β = −2.370 ± 1.195 (95% CI), r = −0.650, *P* \< 0.01\]. There was a positive correlation between the PSC incidence and the income index \[β = 5.285 ± 4.691 (95% CI), r = 0.599, *P* = 0.031\]. In terms of AIH, the incidence also presented a positive correlation with the income index \[β = 7.575 ± 5.589 (95% CI), r = 0.649, *P* = 0.012\].

DISCUSSION {#s3}
==========

This study revealed that socioeconomic development, as indicated by the HDI, might have a positive correlation with the incidence of PBC and AIH. Countries with very high HDI tended to have a higher incidence of PBC and AIH compared to countries with high or medium HDI. In addition, the economic status, as indicated by GNI per capita (income index of HDI), had a positive correlation with the incidence of PSC and AIH. We additionally found some association between national incidence of AILD and the socioeconomic status.

It has been commonly recognized that AILD, mainly consisted of PBC, PSC and AIH, develops as a result from the influence of multiple genes in combination with currently undefined environmental factors. Environmental risk factors might be very complex, but are regarded to trigger the disease onset. PBC is a female predominant liver disease. A controlled interview-based study in the United States revealed that a history of urinary tract infections, cigarette smoking, use of hormone replacement therapies, or frequent use of nail polish were associated with an increased risk for PBC \[[@R47]\]. On the other hand, PSC is a progressive cholestatic liver disease, which is strongly associated with inflammatory bowel disease. A case-control study in the Netherlands has demonstrated that smoking has a protective effect for developing PSC \[[@R1]\]. In terms of AIH, it is mentioned that alcohol drinking and living in a childhood home with wood heating are protective factors against the development of AIH \[[@R2]\]. Other putative environmental factors of AILD include keeping pets, type of housing, number of siblings and family manners. An unidentified agent (i.e., toxin/microbe) might be involved in the development of AILD \[[@R3]\]. Tenca et al. have confirmed that close contact with a pet (especially a cat) during childhood increase the risk of AILD \[[@R3]\]. All these environmental factors as mentioned above might be related to the development of socioeconomic status and subsequent lifestyle changes. Based on this correlation, we made a hypothesis that the incidence of AILD might have a causal relationship with human socioeconomic development.

In this study, a comprehensive review is presented, covering all available relevant studies that report the incidence of AILD without restriction of geographic region or language. On a global level, there was a positive but not significant correlation between PBC incidence and HDI. When excluding the study by Ngu et al conducted in New Zealand \[[@R24]\], whose PBC incidence was especially low compared to other locations in a similar research period, the incidence of PBC demonstrated a positive correlation with HDI. In addition, the PBC incidence in Europe correlated positively with HDI. We found a similar positive correlation in regard to the AIH incidence and the HDI, both worldwide and in Europe. However, we failed to get the similar result in terms of PSC.

A deep analysis on the three dimensions of HDI has been performed. Interestingly, a high GNI per capita had a close association with PSC and AIH prevalence. Furthermore, a higher PBC incidence was related with a higher life expectancy at birth and a lower mean and expected years of schooling. These results summarized in our study might offer clues to the pathogenesis of AILD.

It is the first time a research was conducted, investigating the relationship between the AILD incidence and socioeconomic development. The HDI was selected as the measurement tool because of its worldwide acceptance in international comparisons of development levels. Another strength of this study is that we set up rigorous inclusion criteria, including only population-based studies with definite diagnosis of AILD. Population-based surveys have higher validity because everyone in the at-risk population, or a random sample of the population, is accounted for.

Nevertheless, a few limitations of this study must be taken into consideration. First of all, the review of AILD epidemiology was confined to Europe, North America, Asia and Australia, due to limited data in Africa and Oceania. Secondly, different areas within a country usually have different development levels. However, HDI is the summary of the average socioeconomic status of a country. Moreover, some studies were conducted in a specific region or a single province of a country, which resulted in an uneven distribution of incidence data. Thirdly, we failed to make subgroup analyses according to gender, ethnicity or region (rural/urban gap), on account of the insufficient data. In some way, different populations in an area might have variations in the disease incident rates.

In summary, we have demonstrated a potentially positive relationship between the national incidence of AILD and HDI. This study provides for the first time the evidence that in areas with higher development levels, AILD might be more prevalent, and offers a distinctive perspective on the global epidemiological status of AILD. A more robust and comprehensive analysis is required for further more epidemiological investigations in other continents and based on more detailed information.

MATERIALS AND METHODS {#s4}
=====================

Diagnosis of autoimmune liver diseases {#s4_1}
--------------------------------------

For the purpose of this paper, only studies were included with definite criteria for the diagnosis of autoimmune liver disease. The diagnostic criteria for PBC included: (i) clinical presentation; (ii) elevated serum level of alkaline phosphatase of liver origin for more than 6 months; (iii) presence of serum anti-mitochondrial antibodies (≥1:40); (iv) histological characteristics of florid bile duct lesions. Criteria (ii) and (iii) were diagnostic for PBC, and criteria (iv) confirmed the diagnosis.

The identification of PSC was based on increased serum levels of alkaline phosphatase and γ-glutamyltranspeptidase not otherwise explained, when magnetic resonance cholangiography (MRC) or endoscopic retrograde cholangiography (ERC) demonstrated bile duct changes with multifocal strictures and segmental dilatations. Secondary causes of sclerosing cholangitis and other cholestatic disorders were excluded.

AIH was diagnosed based on the combination of clinical, biochemical (e.g. presence of autoantibodies, elevated immunoglobulin G level) and histological conditions according to the reported criteria \[[@R48]--[@R50]\].

Definition and calculation of HDI {#s4_2}
---------------------------------

The HDI is a compound measure of average achievement in three key dimensions of human development: a long and healthy life (health index: life expectancy at birth), being knowledgeable (education index: mean and expected years of schooling) and having a decent standard of living (income index: gross national income (GNI) per capita).

The HDI data were obtained from the United Nations Development Programme database (<http://hdr.undp.org/en/data>). The average HDI over the research period was calculated, and was defined as the HDI for each study. We hypothesized that HDI progressed linearly in a short period of time and estimated the missing HDI data based on the available data. According to the 2014 Human Development Report (HDR 2014), quartiles of HDI distribution were defined as follows: very high human development (HDI ≥ 0.800), high human development (0.700 ≤ HDI\< 0.800), medium human development (0.550 ≤HDI\< 0.700), and low human development (HDI \< 0.550).

Search strategy and literature evaluation {#s4_3}
-----------------------------------------

Literature was searched using PubMed from inception to January 2016 to identify relevant national epidemiological studies of autoimmune liver disease. No language restriction was imposed. Search terms were as follows: ("Liver Cirrhosis, Biliary/epidemiology"\[Mesh\] OR "primary biliary cirrhosis" OR "primary biliary cholangitis" OR "Cholangitis, Sclerosing/epidemiology"\[Mesh\] OR "primary sclerosing cholangitis" OR "primary sclerotic cholangitis" OR "Hepatitis, Autoimmune/epidemiology"\[Mesh\] OR "autoimmune hepatitis" OR "G4 related cholangitis" OR "G4 associated cholangitis") AND (prevalence OR incidence OR epidemic OR morbidity).

Only studies that present incidence of PBC, PSC or AIH with a definite diagnosis in an adult population were included. Non population-based surveys were disqualified, such as those only enrolled patients in a particular hospital or participants taking part in a particular health plan.

Two investigators independently completed eligibility evaluation and data extraction. Disagreement was solved by discussion with the third investigator. A total of 1708 records were identified through basic search. 1652 publications were excluded after screening through titles and abstracts. Further eligibility evaluation resulted in the exclusion of nine studies because of the absence of data about HDI or disease incidence, and an additional exclusion of four studies because they were not adult population-based. Finally, a total of 43 surveys were included in this study.

Statistical analysis {#s4_4}
--------------------

All statistical analysis was performed by SPSS 21.0 (IBM, Chicago, IL, USA). Associated data was plotted using GraphPad Prism (6.0, GraphPad Software, Inc., San Diego, CA, USA). Kolmogorov--Smirnoff test was conducted to examine the normal distribution of variables. Correlations between the incidence of AILD and HDI were obtained by Pearson coefficient (with normal distribution); in cases of skewed distributions of variables, the Spearman coefficient was applied. In addition, a linear regression analysis was conducted. One-way analysis of variance (ANOVA) or an unpaired t-test was used to compare disease incidence in groups with different socioeconomic development. A *P* value of less than 0.05 was considered as statistically significant.
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